Search

Your search keyword '"Mihai, Carmen Marina"' showing total 29 results
Start Over Author "Mihai, Carmen Marina"
29 results on '"Mihai, Carmen Marina"'

1. Therapeutic management of fibrosis in systemic sclerosis patients - an analysis from the Swiss EUSTAR cohort

Author

Windirsch, Kevin, Jordan, Suzana; https://orcid.org/0000-0002-8114-8239, Becker, Mike Oliver; https://orcid.org/0000-0001-9102-3088, Bruni, Cosimo; https://orcid.org/0000-0003-2813-2083, Dobrota, Rucsandra; https://orcid.org/0000-0001-9819-7574, Elhai, Muriel; https://orcid.org/0000-0001-8627-5758, Garaiman, Ion-Alexandru, Mihai, Carmen-Marina; https://orcid.org/0000-0002-8627-8817, Iudici, Michele, Hasler, Paul; https://orcid.org/0000-0001-7179-3018, Ribi, Camillo, Maurer, Britta; https://orcid.org/0000-0001-9385-8097, Gabrielli, Armando, Hoffmann-Vold, Anna-Maria; https://orcid.org/0000-0001-6467-7422, Distler, Oliver; https://orcid.org/0000-0002-0546-8310, Windirsch, Kevin, Jordan, Suzana; https://orcid.org/0000-0002-8114-8239, Becker, Mike Oliver; https://orcid.org/0000-0001-9102-3088, Bruni, Cosimo; https://orcid.org/0000-0003-2813-2083, Dobrota, Rucsandra; https://orcid.org/0000-0001-9819-7574, Elhai, Muriel; https://orcid.org/0000-0001-8627-5758, Garaiman, Ion-Alexandru, Mihai, Carmen-Marina; https://orcid.org/0000-0002-8627-8817, Iudici, Michele, Hasler, Paul; https://orcid.org/0000-0001-7179-3018, Ribi, Camillo, Maurer, Britta; https://orcid.org/0000-0001-9385-8097, Gabrielli, Armando, Hoffmann-Vold, Anna-Maria; https://orcid.org/0000-0001-6467-7422, and Distler, Oliver; https://orcid.org/0000-0002-0546-8310

Abstract

OBJECTIVES Systemic sclerosis is a chronic autoimmune connective tissue disease leading to microvascular and fibrotic manifestations in multiple organs. Several treatment options and recommendations from different European countries are available. In this study, for which the ambit is Switzerland specifically, we aim to describe the treatment patterns of systemic sclerosis patients with fibrotic manifestations. METHODS Systemic sclerosis patients were selected from six Swiss tertiary centres recorded in the multicentre, prospective European Scleroderma Trials and Research (EUSTAR) registry. Patients fulfilling the 2013 ACR/EULAR systemic sclerosis classification criteria at baseline were included. To determine the differences in treatment of varying degrees of fibrosis, four groups were identified: (1) patients with a modified Rodnan skin score (mRSS) >0; (2) those with mRSS ≥7; (3) those with interstitial lung disease (SSc-ILD), diagnosed by either chest X-Ray or high-resolution computed tomography; and (4) patients fulfilling one of the additional criteria for extensive interstitial lung disease, defined as interstitial lung disease involvement of >20% in high-resolution computed tomography, dyspnea NYHA-stage 3/4, or a predicted forced vital capacity (FVC) of <70%. RESULTS A total of 590 patients with systemic sclerosis fulfilled the inclusion criteria. In this cohort, 421 (71.4%) had mRSS >0, of whom 195 (33.1%) had mRSS ≥7; interstitial lung disease was diagnosed in 198 of 456 (43.4%), of whom 106 (18.0 %) showed extensive interstitial lung disease. Regarding non-biologic disease-modifying medications (DMARDs), the most frequently prescribed was methotrexate, followed by hydroxychloroquine and mycophenolate mofetil. Rituximab and tocilizumab were most frequently used among the biologic DMARDs. Specifically, 148/372 (39.8%) of treated patients with skin fibrosis received methotrexate, mycophenolate mofetil or rituximab, and 80/177 (45.2%) with interstitial lung

Published
2024

3. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Lucero, Eleonora, Pons-Estel, Bernardo, Rivero, Mariano, Tate, Guillermo, Smith, Vanessa, De Langhe, Ellen, Rashkov, Rasho, Batalov, Anastas, Goranov, Ivan, Stoilov, Rumen, Dunne, James, Johnson, Sindhu R., Pope, Janet E., Martinović Kaliterna, Dušanka, Mogensen, Mette, Olesen, Anne Braae, Allanore, Yannick, Henes, Joerg Christoph, Müller-Ladner, Ulf, Riemekasten, Gabriela, Skapenko, Alla, Vlachoyiannopoulos, Panayiotis, Kiss, Emese, Minier, Tünde, Beretta, Lorenzo, Gremese, Elisa, Matucci-Cerinic, Marco, Valentini, Gabriele, Asano, Yoshihide, Atsumi, Tatsuya, Ihn, Hironobu, Ishii, Tomonori, Ishikawa, Osamu, Kuwana, Masataka, Shima, Yoshihito, Takahashi, Hiroki, Takehara, Kazuhiko, Tanaka, Yoshiya, Yamasaki, Yoshioki, Bukauskiene, Loreta, Butrimiene, Irena, Medrano Ramirez, Gabriel, Ramos-Remus, Cesar, Sofia Rodriguez Reyna, Tatiana, de Vries-Bouwstra, Jeska, van Laar, Jacob M., Batko, Bogdan, Jeka, Slawomir, Kucharz, Eugeniusz, Majdan, Maria, Olesinska, Marzena, Smolenska, Zaneta, Alves, Jose, Santos, Maria, Mihai, Carmen Marina, Rednic, Simona, Castellvi Barranco, Ivan, Lopez Longo, Francisco Javier, Simeon Aznar, Carmen, Carreira, Patricia, Distler, Oliver, Walker, Ulrich A., Derrett-Smith, Emma, Griffiths, Bridget, McKay, Neil, Denton, Christopher P., Aelion, Jacob, Borofsky, Michael, Fleischmann, Roy, Forstot, Joseph Z., Furst, Daniel E., Kafaja, Suzanne, Khan, M. Faisal, Khanna, Dinesh, Kohen, Michael D., Martin, Richard W., Mendoza-Ballesteros, Fabian, Nami, Alireza, Pang, Shirley, Rios, Grissel, Simms, Robert, Sullivan, Keith Michael, Steen, Virginia D., Lin, Celia J F, Furst, Daniel E, Goldin, Jonathan, Kim, Grace, van Laar, Jacob M, Spotswood, Helen, Wagner, Bridget, Siegel, Jeffrey, Jahreis, Angelika, and Denton, Christopher P

Published
2020
Full Text
View/download PDF

4. Therapeutic management of fibrosis in systemic sclerosis patients – an analysis from the Swiss EUSTAR cohort

Author

Windirsch, Kevin, primary, Jordan, Suzana, additional, Becker, Mike Oliver, additional, Bruni, Cosimo, additional, Dobrota, Rucsandra, additional, Elhai, Muriel, additional, Garaiman, Ion-Alexandru, additional, Mihai, Carmen-Marina, additional, Iudici, Michele, additional, Hasler, Paul, additional, Ribi, Camillo, additional, Maurer, Britta, additional, Gabrielli, Armando, additional, Hoffmann-Vold, Anna-Maria, additional, and Distler, Oliver, additional

Published
2024
Full Text
View/download PDF

6. Sclerodermic Cardiomyopathy-A State-of-the-Art Review

Author

Giucă, Adrian; https://orcid.org/0000-0001-7146-2411, Gegenava, Tea, Mihai, Carmen Marina, Jurcuţ, Ciprian, Săftoiu, Adrian, Gȋrniţă, Diana Monica; https://orcid.org/0000-0001-8976-176X, Popescu, Bogdan Alexandru, Ajmone Marsan, Nina; https://orcid.org/0000-0001-7208-5769, Jurcuț, Ruxandra, Giucă, Adrian; https://orcid.org/0000-0001-7146-2411, Gegenava, Tea, Mihai, Carmen Marina, Jurcuţ, Ciprian, Săftoiu, Adrian, Gȋrniţă, Diana Monica; https://orcid.org/0000-0001-8976-176X, Popescu, Bogdan Alexandru, Ajmone Marsan, Nina; https://orcid.org/0000-0001-7208-5769, and Jurcuț, Ruxandra

Abstract

Systemic sclerosis (SSc) is a chronic autoimmune disorder with unknown triggering factors, and complex pathophysiologic links which lead to fibrosis of skin and internal organs, including the heart, lungs, and gut. However, more than 100 years after the first description of cardiac disease in SSc, sclerodermic cardiomyopathy (SScCmp) is an underrecognized, occult disease with important adverse long-term prognosis. Laboratory tests, electrocardiography (ECG) and cardiovascular multimodality imaging techniques (transthoracic 2D and 3D echocardiography, cardiac magnetic resonance (CMR), and novel imaging techniques, including myocardial deformation analysis) provide new insights into the cardiac abnormalities in patients with SSc. This state-of-the-art review aims to stratify all the cardiac investigations needed to diagnose and follow-up the SScCmp, and discusses the epidemiology, risk factors and pathophysiology of this important cause of morbidity of the SSc patient. Keywords: cardiac magnetic resonance; cardiomyopathy; echocardiography; speckle-tracking; strain; systemic sclerosis

Published
2022

7. Sclerodermic Cardiomyopathy-A State-of-the-Art Review

Author

Giucă, Adrian, Gegenava, Tea, Mihai, Carmen Marina, Jurcuţ, Ciprian, Săftoiu, Adrian, Gȋrniţă, Diana Monica, Popescu, Bogdan Alexandru, Ajmone Marsan, Nina, Jurcuț, Ruxandra, University of Zurich, and Jurcuț, Ruxandra

Subjects
10051 Rheumatology Clinic and Institute of Physical Medicine, 610 Medicine & health, 1308 Clinical Biochemistry
Published
2022
Full Text
View/download PDF

8. Sclerodermic Cardiomyopathy—A State-of-the-Art Review

Author

Giucă, Adrian, primary, Gegenava, Tea, additional, Mihai, Carmen Marina, additional, Jurcuţ, Ciprian, additional, Săftoiu, Adrian, additional, Gȋrniţă, Diana Monica, additional, Popescu, Bogdan Alexandru, additional, Ajmone Marsan, Nina, additional, and Jurcuț, Ruxandra, additional

Published
2022
Full Text
View/download PDF

9. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study

Author

Avouac, Jérôme, Walker, Ulrich A, Hachulla, Eric, Riemekasten, Gabriela, Cuomo, Giovanna, Carreira, Patricia E, Caramaschi, Paola, Ananieva, Lidia P, Matucci-Cerinic, Marco, Czirjak, Laszlo, Denton, Christopher, Ladner, Ulf Müller, Allanore, Yannick, Guiducci, Serena, Tyndall, Alan, Lapadula, Giovanni, Iannone, Florenzo, Distler, Oliver, Becvar, Radim, Sierakowsky, Stanislaw, Bielecka, Otylia Kowal, Cutolo, Maurizio, Sulli, Alberto, Valentini, Gabriele, Vlachoyiannopoulos, Panayiotis G., Montecucco, Carlomaurizio, Caporali, Roberto, Novak, Srdan, Chizzolini, Carlo, Kucharz, Eugene J., Kotulska, Anna, Cozzi, Franco, Rozman, Blaz, Mallia, Carmel, Coleiro, Bernard, Gabrielli, Armando, Farge-Bancel, Dominique, Hadj-Khelifa, Sondess, Airò, Paolo, Hesselstrand, Roger, Scheja, Agneta, Martinovic, Duska, Gurman, Alexandra Balbir, Braun-Moscovici, Yolanda, Hunzelmann, Nicolas, Pellerito, Raffaele, Bambara, Lisa Maria, Morovic-Vergles, Jadranka, Black, Carol, Damjanov, Nemanja, Kötter, Ina, Santamaria, Vera Ortiz, Heitmann, Stefan, Krasowska, Dorota, Seidel, Matthias, Hasler, Paul, Burkhardt, Harald, Himsel, Andrea, Silva, José Antonio Pereira Da, Salvador, Maria João, Stamenkovi, Bojana, Stankovic, Aleksandra, Marasini, Bianca, Belloli, Laura, Tikly, Mohammed, Denisov, Lev N., Scorza, Raffaella, Engelhart, Merete, Strauss, Gitte, Szücs, Gabriella, Szamosi, Szilvia, de la Puente, Carlos, de la Pena Lefebvre, Paloma García, Midtvedt, Øyvind, Garen, Torhild, Launay, David, Valesini, Guido, Riccieri, Valeria, Ionescu, Ruxandra Maria, Opris, Daniela, Wigley, Fredrick M., Stoica, Viktor, Mihai, Carmen Marina, Distler, Jörg, Meroni, Pierluigi, Zeni, Silvana, Mouthon, Luc, Smith, Vanessa, Cantatore, Francesco Paolo, Corrado, Ada, Ullman, Susanne, Iversen, Line, Pozzi, Maria Rosa, Eyerich, Kilian, Hein, Rüdiger, Szechinski, Jacek, Wiland, Piotr, Krummel-Lorenz, Brigitte, Aringer, Martin, Westhovens, Rene, De Langhe, Ellen, Anic, Branimir, Baresi, Marko, Üprus, Maria, Otsa, Kati, Yavuz, Sule, Radominski, Sebastião Cezar, de Souza Müller, Carolina, Jimenez, Sergio, Busquets, Joanna, Popa, Sergei, Agachi, Svetlana, Zenone, Thierry, Mathieu, Alessandro, Vacca, Alessandra, Stamp, Lisa, Chapman, Peter, Tanaseanu, Cristina-Mihaela, Popescu, Monica, Foti, Rosario, and Rubio, Silvia Rodriguez

Published
2016
Full Text
View/download PDF

10. Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population

Author

Hachulla, Eric, Clerson, Pierre, Airò, Paolo, Cuomo, Giovanna, Allanore, Yannick, Caramaschi, Paola, Rosato, Edoardo, Carreira, Patricia E., Riccieri, Valeria, Sarraco, Marta, Denton, Christopher P., Riemekasten, Gabriela, Pozzi, Maria Rosa, Zeni, Silvana, Mihai, Carmen Marina, Ullman, Susanne, Distler, Oliver, Rednic, Simona, Smith, Vanessa, Walker, Ulrich A., Matucci-Cerinic, Marco, Müller-Ladner, Ulf, and Launay, David

Published
2015
Full Text
View/download PDF

11. Tocilizumab in systemic sclerosis:a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Khanna, Dinesh, Lin, Celia J.F., Furst, Daniel E., Goldin, Jonathan, Kim, Grace, Kuwana, Masataka, Allanore, Yannick, Matucci-Cerinic, Marco, Distler, Oliver, Shima, Yoshihito, van Laar, Jacob M., Spotswood, Helen, Wagner, Bridget, Siegel, Jeffrey, Jahreis, Angelika, Denton, Christopher P., Lucero, Eleonora, Pons-Estel, Bernardo, Rivero, Mariano, Tate, Guillermo, Smith, Vanessa, De Langhe, Ellen, Rashkov, Rasho, Batalov, Anastas, Goranov, Ivan, Stoilov, Rumen, Dunne, James, Johnson, Sindhu R., Pope, Janet E., Martinović Kaliterna, Dušanka, Mogensen, Mette, Olesen, Anne Braae, Henes, Joerg Christoph, Müller-Ladner, Ulf, Riemekasten, Gabriela, Skapenko, Alla, Vlachoyiannopoulos, Panayiotis, Kiss, Emese, Minier, Tünde, Beretta, Lorenzo, Gremese, Elisa, Valentini, Gabriele, Asano, Yoshihide, Atsumi, Tatsuya, Ihn, Hironobu, Ishii, Tomonori, Ishikawa, Osamu, Takahashi, Hiroki, Takehara, Kazuhiko, Tanaka, Yoshiya, Yamasaki, Yoshioki, Bukauskiene, Loreta, Butrimiene, Irena, Medrano Ramirez, Gabriel, Ramos-Remus, Cesar, Sofia Rodriguez Reyna, Tatiana, de Vries-Bouwstra, Jeska, Batko, Bogdan, Jeka, Slawomir, Kucharz, Eugeniusz, Majdan, Maria, Olesinska, Marzena, Smolenska, Zaneta, Alves, Jose, Santos, Maria, Mihai, Carmen Marina, Rednic, Simona, Castellvi Barranco, Ivan, Lopez Longo, Francisco Javier, Simeon Aznar, Carmen, Carreira, Patricia, Walker, Ulrich A., Derrett-Smith, Emma, Griffiths, Bridget, McKay, Neil, Aelion, Jacob, Borofsky, Michael, Fleischmann, Roy, Forstot, Joseph Z., Kafaja, Suzanne, Khan, M. Faisal, Kohen, Michael D., Martin, Richard W., Mendoza-Ballesteros, Fabian, Nami, Alireza, Pang, Shirley, Rios, Grissel, Simms, Robert, Sullivan, Keith Michael, Steen, Virginia D., Khanna, Dinesh, Lin, Celia J.F., Furst, Daniel E., Goldin, Jonathan, Kim, Grace, Kuwana, Masataka, Allanore, Yannick, Matucci-Cerinic, Marco, Distler, Oliver, Shima, Yoshihito, van Laar, Jacob M., Spotswood, Helen, Wagner, Bridget, Siegel, Jeffrey, Jahreis, Angelika, Denton, Christopher P., Lucero, Eleonora, Pons-Estel, Bernardo, Rivero, Mariano, Tate, Guillermo, Smith, Vanessa, De Langhe, Ellen, Rashkov, Rasho, Batalov, Anastas, Goranov, Ivan, Stoilov, Rumen, Dunne, James, Johnson, Sindhu R., Pope, Janet E., Martinović Kaliterna, Dušanka, Mogensen, Mette, Olesen, Anne Braae, Henes, Joerg Christoph, Müller-Ladner, Ulf, Riemekasten, Gabriela, Skapenko, Alla, Vlachoyiannopoulos, Panayiotis, Kiss, Emese, Minier, Tünde, Beretta, Lorenzo, Gremese, Elisa, Valentini, Gabriele, Asano, Yoshihide, Atsumi, Tatsuya, Ihn, Hironobu, Ishii, Tomonori, Ishikawa, Osamu, Takahashi, Hiroki, Takehara, Kazuhiko, Tanaka, Yoshiya, Yamasaki, Yoshioki, Bukauskiene, Loreta, Butrimiene, Irena, Medrano Ramirez, Gabriel, Ramos-Remus, Cesar, Sofia Rodriguez Reyna, Tatiana, de Vries-Bouwstra, Jeska, Batko, Bogdan, Jeka, Slawomir, Kucharz, Eugeniusz, Majdan, Maria, Olesinska, Marzena, Smolenska, Zaneta, Alves, Jose, Santos, Maria, Mihai, Carmen Marina, Rednic, Simona, Castellvi Barranco, Ivan, Lopez Longo, Francisco Javier, Simeon Aznar, Carmen, Carreira, Patricia, Walker, Ulrich A., Derrett-Smith, Emma, Griffiths, Bridget, McKay, Neil, Aelion, Jacob, Borofsky, Michael, Fleischmann, Roy, Forstot, Joseph Z., Kafaja, Suzanne, Khan, M. Faisal, Kohen, Michael D., Martin, Richard W., Mendoza-Ballesteros, Fabian, Nami, Alireza, Pang, Shirley, Rios, Grissel, Simms, Robert, Sullivan, Keith Michael, and Steen, Virginia D.

Abstract

Background: A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in systemic sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial lung disease (SSc-ILD) in a phase 3 trial to investigate the safety and efficacy of tocilizumab, an anti-interleukin-6 receptor antibody, in the treatment of systemic sclerosis. Methods: In this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, participants were recruited from 75 sites in 20 countries across Europe, North America, Latin America, and Japan. Adults with diffuse cutaneous systemic sclerosis for 60 months or less and a modified Rodnan skin score (mRSS) of 10–35 at screening were randomly assigned (1:1) with a voice-web-response system to receive subcutaneous tocilizumab 162 mg or placebo weekly for 48 weeks, stratified by IL-6 levels; participants and investigators were masked to treatment group. The primary endpoint was the difference in change from baseline to week 48 in mRSS. Percentage of predicted forced vital capacity (FVC% predicted) at week 48, time to treatment failure, and patient-reported and physician-reported outcomes were secondary endpoints. This trial is registered with ClinicalTrials.gov (number NCT02453256) and is closed to accrual. Findings: Between Nov 20, 2015, and Feb 14, 2017, 210 individuals were randomly assigned to receive tocilizumab (n=104) or placebo (n=106). In the intention-to-treat population, least squares mean [LSM] change from baseline to week 48 in mRSS was −6·14 for tocilizumab and −4·41 for placebo (adjusted difference −1·73 [95% CI −3·78 to 0·32]; p=0·10). The shift in distribution of change from baseline in FVC% predicted at week 48 favoured tocilizumab (van Elteren nominal p=0·002 vs placebo), with a difference in LSM of 4·2 (95% CI 2·0–6·4; nominal p=0·0002), as did time to treatment failure (hazard ratio 0·63 [95% CI 0·37–1·06]; nominal p=0·08). Change in LSM from baseline to week 48 in Health Assessment Ques

Published
2020

13. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Khanna, Dinesh, primary, Lin, Celia J F, additional, Furst, Daniel E, additional, Goldin, Jonathan, additional, Kim, Grace, additional, Kuwana, Masataka, additional, Allanore, Yannick, additional, Matucci-Cerinic, Marco, additional, Distler, Oliver, additional, Shima, Yoshihito, additional, van Laar, Jacob M, additional, Spotswood, Helen, additional, Wagner, Bridget, additional, Siegel, Jeffrey, additional, Jahreis, Angelika, additional, Denton, Christopher P, additional, Lucero, Eleonora, additional, Pons-Estel, Bernardo, additional, Rivero, Mariano, additional, Tate, Guillermo, additional, Smith, Vanessa, additional, De Langhe, Ellen, additional, Rashkov, Rasho, additional, Batalov, Anastas, additional, Goranov, Ivan, additional, Stoilov, Rumen, additional, Dunne, James, additional, Johnson, Sindhu R., additional, Pope, Janet E., additional, Martinović Kaliterna, Dušanka, additional, Mogensen, Mette, additional, Olesen, Anne Braae, additional, Henes, Joerg Christoph, additional, Müller-Ladner, Ulf, additional, Riemekasten, Gabriela, additional, Skapenko, Alla, additional, Vlachoyiannopoulos, Panayiotis, additional, Kiss, Emese, additional, Minier, Tünde, additional, Beretta, Lorenzo, additional, Gremese, Elisa, additional, Valentini, Gabriele, additional, Asano, Yoshihide, additional, Atsumi, Tatsuya, additional, Ihn, Hironobu, additional, Ishii, Tomonori, additional, Ishikawa, Osamu, additional, Takahashi, Hiroki, additional, Takehara, Kazuhiko, additional, Tanaka, Yoshiya, additional, Yamasaki, Yoshioki, additional, Bukauskiene, Loreta, additional, Butrimiene, Irena, additional, Medrano Ramirez, Gabriel, additional, Ramos-Remus, Cesar, additional, Sofia Rodriguez Reyna, Tatiana, additional, de Vries-Bouwstra, Jeska, additional, van Laar, Jacob M., additional, Batko, Bogdan, additional, Jeka, Slawomir, additional, Kucharz, Eugeniusz, additional, Majdan, Maria, additional, Olesinska, Marzena, additional, Smolenska, Zaneta, additional, Alves, Jose, additional, Santos, Maria, additional, Mihai, Carmen Marina, additional, Rednic, Simona, additional, Castellvi Barranco, Ivan, additional, Lopez Longo, Francisco Javier, additional, Simeon Aznar, Carmen, additional, Carreira, Patricia, additional, Walker, Ulrich A., additional, Derrett-Smith, Emma, additional, Griffiths, Bridget, additional, McKay, Neil, additional, Denton, Christopher P., additional, Aelion, Jacob, additional, Borofsky, Michael, additional, Fleischmann, Roy, additional, Forstot, Joseph Z., additional, Furst, Daniel E., additional, Kafaja, Suzanne, additional, Khan, M. Faisal, additional, Khanna, Dinesh, additional, Kohen, Michael D., additional, Martin, Richard W., additional, Mendoza-Ballesteros, Fabian, additional, Nami, Alireza, additional, Pang, Shirley, additional, Rios, Grissel, additional, Simms, Robert, additional, Sullivan, Keith Michael, additional, and Steen, Virginia D., additional

Published
2020
Full Text
View/download PDF

18. Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc)

Author

Denton, Christopher P., primary, Lin, Celia J. F., additional, Goldin, Jonathan, additional, Kim, Grace, additional, Kuwana, Masataka, additional, Allanore, Yannick, additional, Batalov, Anastas, additional, Butrimiene, Irena, additional, Carreira, Patricia, additional, Matucci-Cerinic, Marco, additional, Distler, Oliver, additional, Martinović Kaliterna, Dušanka, additional, Mihai, Carmen-Marina, additional, Mogensen, Mette, additional, Olesińska, Marzena, additional, Pope, Janet E., additional, Riemekasten, Gabriela, additional, Rodriguez-Reyne, Tatiana Sofía, additional, Santos, Maria José, additional, Van Laar, Jacob, additional, Spotswood, Helen, additional, Siegel, Jeffrey, additional, Jahreis, Angelika, additional, Furst, Daniel E., additional, and Khanna, Dinesh, additional

Published
2019
Full Text
View/download PDF

20. Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population

Author

Hachulla, Eric, Clerson, Pierre, Airò, Paolo, Cuomo, Giovanna, Allanore, Yannick, Caramaschi, Paola, Rosato, Edoardo, Carreira, Patricia E., Riccieri, Valeria, Sarraco, Marta, Denton, Christopher P., Riemekasten, Gabriela, Pozzi, Maria Rosa, Zeni, Silvana, Mihai, Carmen Marina, Ullman, Susanne, Distler, Oliver, Rednic, Simona, Smith, Vanessa, Walker, Ulrich A., Matucci-Cerinic, Marco, Müller-Ladner, Ulf, Launay, David, Hachulla, Eric, Clerson, Pierre, Airò, Paolo, Cuomo, Giovanna, Allanore, Yannick, Caramaschi, Paola, Rosato, Edoardo, Carreira, Patricia E., Riccieri, Valeria, Sarraco, Marta, Denton, Christopher P., Riemekasten, Gabriela, Pozzi, Maria Rosa, Zeni, Silvana, Mihai, Carmen Marina, Ullman, Susanne, Distler, Oliver, Rednic, Simona, Smith, Vanessa, Walker, Ulrich A., Matucci-Cerinic, Marco, Müller-Ladner, Ulf, and Launay, David

Abstract

Objective. The aim of this study was to assess the prognostic value of systolic pulmonary artery pressure (sPAP) estimated by echocardiography in the multinational European League Against Rheumatism Scleroderma Trial and Research (EUSTAR) cohort. Methods. Data for patients with echocardiography documented between 1 January 2005 and 31 December 2011 were extracted from the EUSTAR database. Stepwise forward multivariable statistical Cox pulmonary hypertension analysis was used to examine the independent effect on survival of selected variables. Results. Based on our selection criteria, 1476 patients were included in the analysis; 87% of patients were female, with a mean age of 56.3 years (s.d. 13.5) and 31% had diffuse SSc. The mean duration of follow-up was 2.0 years (s.d. 1.2, median 1.9). Taking index sPAP of <30 mmHg as reference, the hazard ratio (HR) for death was 1.67 (95% CI 0.92, 2.96) if the index sPAP was between 30 and 36 mmHg, 2.37 (95% CI 1.14, 4.93) for sPAP between 36 and 40 mmHg, 3.72 (95% CI 1.61, 8.60) for sPAP between 40 and 50 mmHg and 9.75 (95% CI 4.98, 19.09) if sPAP was >50 mmHg. In a multivariable Cox model, sPAP and the diffusing capacity for carbon monoxide (DLCO) were independently associated with the risk of death [HR 1.833 (95% CI 1.035, 3.247) and HR 0.973 (95% CI 0.955, 0.991), respectively]. sPAP was an independent risk factor for death with a HR of 3.02 (95% CI 1.91, 4.78) for sPAP ≥36 mmHg. Conclusion. An estimated sPAP >36 mmHg at baseline echocardiography was significantly and independently associated with reduced survival, regardless of the presence of pulmonary hypertension based on right heart catheterization

Published
2017

22. A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study

Author

Ingegnoli, Francesca, primary, Boracchi, Patrizia, additional, Gualtierotti, Roberta, additional, Smith, Vanessa, additional, Cutolo, Maurizio, additional, Foeldvari, Ivan, additional, Airò, Paolo, additional, Alegre-Sancho, Juan Jose, additional, Allanore, Yannick, additional, Ananieva, Lidia P., additional, Ancuta, Codrina, additional, Andrade, Luis Eduardo, additional, Aringer, Martin, additional, Becvar, Radim, additional, Bojinca, Mihai, additional, Butrimiene, Irena, additional, Cantatore, Francesco Paolo, additional, Caporali, Roberto, additional, Caramaschi, Paola, additional, Carreira, Patricia E., additional, Chirieac, Rodica, additional, Corrado, Ada, additional, Cosentino, Vanesa, additional, Cuomo, Giovanna, additional, Czirjak, Laszlo, additional, Da Silva, José Antonio Pereira, additional, la Peña Lefebvre, Paloma García de, additional, De Keyser, Filip, additional, de Souza Müller, Carolina, additional, Damgaard, Kirsten, additional, Damjanov, Nemanja, additional, Denisov, Lev N., additional, Distler, Oliver, additional, Doube, Alan, additional, Dumitrascu, Alina, additional, Engelhart, Merete, additional, Exposito, Marta Valero, additional, Eyerich, Kilian, additional, Farge-Bancel, Dominique, additional, Azevedo, Valderílio Feijó, additional, Foti, Rosario, additional, Frerix, Marc, additional, Gabrielli, Armando, additional, Garen, Torhild, additional, Gottschalk, Paola, additional, Groseanu, Laura, additional, Guiducci, Serena, additional, Günther, Claudia, additional, Hachulla, Eric, additional, Hein, Rüdiger, additional, Heitmann, Stefan, additional, Henes, Jörg, additional, Hesselstrand, Roger, additional, Highton, John, additional, Iannone, Florenzo, additional, Ionescu, Ruxandra Maria, additional, Kayser, Cristiane, additional, Karpec, Diana, additional, Kerzberg, Eduardo, additional, Kotulska, Anna, additional, Kopec-Medrek, Magdalena, additional, Kucharz, Eugene, additional, Krummel-Lorenz, Brigitte, additional, Lauffer, Felix, additional, Launay, David, additional, Li, Mengtao, additional, Litinsky, Ira, additional, Loyo, Esthela, additional, Cerinic, Marco Matucci, additional, Meroni, Pierluigi, additional, Midtvedt, Øyvind, additional, Mihai, Carmen Marina, additional, Montecucco, Carlomaurizio, additional, Montoya, Fabiana, additional, Morgiel, Ewa, additional, Mouthon, Luc, additional, Müller-Ladner, Ulf, additional, Nielsen, Henrik, additional, Opris, Daniela, additional, Ortiz-Santamaria, Vera, additional, Otsa, Kati, additional, Pileckyte, Margarita, additional, Pisarri, Simonetta, additional, Popescu, Monica, additional, Pozzi, Maria Rosa, additional, Puppo, Francesco, additional, Radominski, Sebastião Cezar, additional, Riccieri, Valeria, additional, Rosato, Edoardo, additional, Rozman, Blaz, additional, Rubio, Silvia Rodriguez, additional, Rugiene, Rita, additional, Saar, Petra, additional, Salvador, Maria João, additional, Seidel, Matthias, additional, Sokolik, Renata, additional, Solanki, Kamal, additional, Stamenkovic, Bojana, additional, Stankovic, Aleksandra, additional, Stebbings, Simon, additional, Strauss, Gitte, additional, Sulli, Alberto, additional, Szamosi, Szilvia, additional, Szechinski, Jacek, additional, Szmyrka-Kaczmarek, Magdalena, additional, Szücs, Gabriella, additional, Tanaseanu, Cristina-Mihaela, additional, Tiglea, Isabela, additional, Tyndall, Alan, additional, Ughi, Nicola, additional, Uprus, Maria, additional, Vacca, Alessandra, additional, Varju, Cecilia, additional, Venalis, Algirdas, additional, Venalis, Paulius, additional, Walker, Ulrich A., additional, Widuchowska, Malgorzata, additional, Wiland, Piotr, additional, Wuttge, Dirk M., additional, Zeni, Silvana, additional, and Zenone, Thierry, additional

Published
2015
Full Text
View/download PDF

23. TNF-Inhibitoren verlangsamen die radiologische Progression bei Patienten mit ankylosierender Spondylitis

Author

Mihai, Carmen-Marina

Abstract

Objectives:Tumour necrosis factor inhibitors (TNFis) have been suggested to slow radiographic progression in patients with ankylosing spondylitis. However, limitations such as variations in disease activity, complex drug administration and short follow-up duration make it difficult to determine the effect of TNFis on radiographic progression. The aim of the study was to investigate whether long-term treatment with TNFis can reduce radiographic progression in patients with ankylosing spondylitis using 18-year longitudinal real-world data. Methods:This retrospective study was conducted between January 2001 and December 2018 at a single centre. Among the 1280 patients whose electronic medical records were reviewed, data of 595 patients exposed to TNFis at least once were included. Among them, time intervals of TNFi exposure or non-exposure were determined in 338 patients (‹on the TNFis› or ‹off the TNFis› intervals, respectively). The difference in the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) change rate between ‹on the TNFis› and ‹off the TNFis› intervals was investigated. Results:We obtained 2364 intervals of 338 patients (1281 ‹on the TNFis› and 1083 ‹off the TNFis› intervals). In the marginal structural model for inverse probability of treatment weighting, the change rate of mSASSS significantly decreased with the use of TNFis (β = –0.112, p = 0.004), and the adjusted mSASSS changes were 0.848 and 0.960 per year during ‹on the TNFis› and ‹off the TNFis› intervals, respectively. Conclusion:Compared with treatment without TNFis, treatment with TNFis slowed radiologic progression significantly.

Published
2021
Full Text
View/download PDF

24. Nailfold capillaroscopy in systemic sclerosis: Data from the EULAR scleroderma trials and research (EUSTAR) database

Author

Ingegnoli, Francesca, primary, Ardoino, Ilaria, additional, Boracchi, Patrizia, additional, Cutolo, Maurizio, additional, Airò, Paolo, additional, Ananieva, Lidia P., additional, Ancuta, Codrina, additional, Andrade, Luis Eduardo, additional, Becvar, Radim, additional, Benenati, Alessia, additional, Caramaschi, Paola, additional, Carreira, Patricia E., additional, Cuomo, Giovanna, additional, Damjanov, Nemanja, additional, Distler, Oliver, additional, Foti, Rosario, additional, Guiducci, Serena, additional, Hachulla, Eric, additional, Highton, John, additional, Kayser, Cristiane, additional, Lubatti, Chiara, additional, Cerinic, Marco Matucci, additional, Meier, Florian, additional, Meroni, Pier Luigi, additional, Mihai, Carmen Marina, additional, Morgiel, Ewa, additional, Müller-Ladner, Ulf, additional, Loyo, Esthela, additional, Ortiz, Vera, additional, Riccieri, Valeria, additional, Scheja, Agneta, additional, Skacelova, Simona, additional, Smith, Vanessa, additional, Stamenkovic, Bojana, additional, Stebbings, Simon, additional, Stoica, Viktor, additional, Sulli, Alberto, additional, Szechinski, Jacek, additional, Tyndall, Alan, additional, Valentini, Gabriele, additional, Walker, Ulrich, additional, Zeni, Silvana, additional, and Zlatanovic, Maja, additional

Published
2013
Full Text
View/download PDF

25. Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients.

Author

Arama, Stefan Sorin, Tiliscan, Catalin, Negoita, Cristina, Croitoru, Alexandru, Arama, Victoria, Mihai, Carmen Marina, Pop, Florinel, and Garg, Amit

Subjects
TREATMENT of helicobacter pylori infections, HELICOBACTER pylori infections, TREATMENT effectiveness, ROMANIANS, COHORT analysis, COMPARATIVE studies, HEALTH, PATIENTS
Abstract

Objective. This study compared the eradication rates of of Helicobacter pylori (HP) infection by a 7-day and 14-day anti-HP regimen. Materials and Methods. An open, randomized, prospective study was performed to evaluate the response to anti-HP treatment in adult HP-positive patients following a 7-day course (Regimen A) of a proton pump inhibitor in association with clarithromycin and amoxicillin compared to a 14-day course (Regimen B). Gastric biopsies were performed at baseline and two months after anti-HP treatment. Results. Seventy-eight patients aged 18–64 years (28 males, 50 females) diagnosed with HP infection were included. Fifty-two (66.7%) patients received Regimen B and 26 (33.3%) Regimen A. The overall eradication rate was 70.5%. Better treatment response (p<0.01) was seen in Regimen B (44/52, 84.2% versus 11/26, 42.3%). Significant improvement in histological features was seen in regimen B. There has been significant overall reduction in endoscopic aspects of gastric and duodenal lesions in both regimens. Younger patients ≤35 years had a better response to Regimen B. Better treatment response was seen in women, urban residents, and those with tertiary level of education in both groups. Conclusion. 14-day anti-HP regimen offered a significant better overall eradication of HP in study population. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

26. Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population

Author

Hachulla, Eric, Clerson, Pierre, Airò, Paolo, Cuomo, Giovanna, Allanore, Yannick, Caramaschi, Paola, Rosato, Edoardo, Carreira, Patricia E., Riccieri, Valeria, Sarraco, Marta, Denton, Christopher P., Riemekasten, Gabriela, Pozzi, Maria Rosa, Zeni, Silvana, Mihai, Carmen Marina, Ullman, Susanne, Distler, Oliver, Rednic, Simona, Smith, Vanessa, Walker, Ulrich A., Matucci-Cerinic, Marco, Müller-Ladner, Ulf, Launay, David, Hachulla, Eric, Clerson, Pierre, Airò, Paolo, Cuomo, Giovanna, Allanore, Yannick, Caramaschi, Paola, Rosato, Edoardo, Carreira, Patricia E., Riccieri, Valeria, Sarraco, Marta, Denton, Christopher P., Riemekasten, Gabriela, Pozzi, Maria Rosa, Zeni, Silvana, Mihai, Carmen Marina, Ullman, Susanne, Distler, Oliver, Rednic, Simona, Smith, Vanessa, Walker, Ulrich A., Matucci-Cerinic, Marco, Müller-Ladner, Ulf, and Launay, David

Abstract

Objective. The aim of this study was to assess the prognostic value of systolic pulmonary artery pressure (sPAP) estimated by echocardiography in the multinational European League Against Rheumatism Scleroderma Trial and Research (EUSTAR) cohort. Methods. Data for patients with echocardiography documented between 1 January 2005 and 31 December 2011 were extracted from the EUSTAR database. Stepwise forward multivariable statistical Cox pulmonary hypertension analysis was used to examine the independent effect on survival of selected variables. Results. Based on our selection criteria, 1476 patients were included in the analysis; 87% of patients were female, with a mean age of 56.3 years (s.d. 13.5) and 31% had diffuse SSc. The mean duration of follow-up was 2.0 years (s.d. 1.2, median 1.9). Taking index sPAP of <30 mmHg as reference, the hazard ratio (HR) for death was 1.67 (95% CI 0.92, 2.96) if the index sPAP was between 30 and 36 mmHg, 2.37 (95% CI 1.14, 4.93) for sPAP between 36 and 40 mmHg, 3.72 (95% CI 1.61, 8.60) for sPAP between 40 and 50 mmHg and 9.75 (95% CI 4.98, 19.09) if sPAP was >50 mmHg. In a multivariable Cox model, sPAP and the diffusing capacity for carbon monoxide (DLCO) were independently associated with the risk of death [HR 1.833 (95% CI 1.035, 3.247) and HR 0.973 (95% CI 0.955, 0.991), respectively]. sPAP was an independent risk factor for death with a HR of 3.02 (95% CI 1.91, 4.78) for sPAP ≥36 mmHg. Conclusion. An estimated sPAP >36 mmHg at baseline echocardiography was significantly and independently associated with reduced survival, regardless of the presence of pulmonary hypertension based on right heart catheterization

27. Nailfold capillaroscopy in systemic sclerosis: data from the EULAR scleroderma trials and research (EUSTAR) database

Author

Francesca Ingegnoli, Ilaria Ardoino, Patrizia Boracchi, Maurizio Cutolo, Paolo Airò, Lidia P. Ananieva, Codrina Ancuta, Luis Eduardo Andrade, Radim Becvar, Alessia Benenati, Paola Caramaschi, Patricia E. Carreira, Giovanna Cuomo, Nemanja Damjanov, Oliver Distler, Rosario Foti, Serena Guiducci, Eric Hachulla, John Highton, Cristiane Kayser, Chiara Lubatti, Marco Matucci Cerinic, Florian Meier, Pier Luigi Meroni, Carmen Marina Mihai, Ewa Morgiel, Ulf Müller-Ladner, Esthela Loyo, Vera Ortiz, Valeria Riccieri, Agneta Scheja, Simona Skacelova, Vanessa Smith, Bojana Stamenkovic, Simon Stebbings, Viktor Stoica, Alberto Sulli, Jacek Szechinski, Alan Tyndall, Gabriele Valentini, Ulrich Walker, Silvana Zeni, Maja Zlatanovic, Ingegnoli, Francesca, Ardoino, Ilaria, Boracchi, Patrizia, Cutolo, Maurizio, Airã², Paolo, Ananieva, Lidia P., Ancuta, Codrina, Andrade, Luis Eduardo, Becvar, Radim, Benenati, Alessia, Caramaschi, Paola, Carreira, Patricia E., Cuomo, Giovanna, Damjanov, Nemanja, Distler, Oliver, Foti, Rosario, Guiducci, Serena, Hachulla, Eric, Highton, John, Kayser, Cristiane, Lubatti, Chiara, Cerinic, Marco Matucci, Meier, Florian, Meroni, Pier Luigi, Mihai, Carmen Marina, Morgiel, Ewa, Müller Ladner, Ulf, Loyo, Esthela, Ortiz, Vera, Riccieri, Valeria, Scheja, Agneta, Skacelova, Simona, Smith, Vanessa, Stamenkovic, Bojana, Stebbings, Simon, Stoica, Viktor, Sulli, Alberto, Szechinski, Jacek, Tyndall, Alan, Valentini, Gabriele, Walker, Ulrich, Zeni, Silvana, and Zlatanovic, Maja

Subjects
Male, VIDEOCAPILLAROSCOPIC PATTERNS, Databases, Factual, RAYNAUDS-PHENOMENON, systemic sclerosis, International Cooperation, Nailfold videocapillaroscopy, Disease, computer.software_genre, ANTINUCLEAR ANTIBODIES, Biochemistry, Scleroderma, Microscopic Angioscopy, Cohort Studies, Surveys and Questionnaires, Medicine and Health Sciences, Surveys and Questionnaire, Medicine, ORGAN INVOLVEMENT, Nailfold Capillaroscopy, Clinical Trials as Topic, integumentary system, Database, ABNORMALITIES, MICROSCOPY, Middle Aged, Phenotype, Cohort, Disease Progression, Female, Cardiology and Cardiovascular Medicine, Human, Adult, Disease cluster, Nailfold capillaroscopy, Humans, In patient, Aged, Cross-Sectional Studie, Scleroderma, Systemic, business.industry, Cell Biology, medicine.disease, Capillaries, ACTIVITY CRITERIA, Capillarie, Cross-Sectional Studies, SEVERITY, DENSITY, Organ involvement, CONNECTIVE-TISSUE DISEASE, Cohort Studie, business, computer
Abstract

Objective The aims of this study were to obtain cross-sectional data on capillaroscopy in an international multi-center cohort of Systemic Sclerosis (SSc) and to investigate the frequency of the capillaroscopic patterns and their disease-phenotype associations. Methods Data collected between June 2004 and October 2011 in the EULAR Scleroderma Trials and Research (EUSTAR) registry were examined. Patients' profiles based on clinical and laboratory data were obtained by cluster analysis and the association between profiles and capillaroscopy was investigated by multinomial logistic regression. Results 62 of the 110 EUSTAR centers entered data on capillaroscopy in the EUSTAR database. 376 of the 2754 patients (13.65%) were classified as scleroderma pattern absent, but non-specific capillary abnormalities were noted in 55.48% of the cases. Four major patients' profiles were identified characterized by a progressive severity for skin involvement, as well as an increased number of systemic manifestations. The “early” and “active” scleroderma patterns were generally observed in patients with mild/moderate skin involvement and a low number of disease manifestations, while the “late” scleroderma pattern was found more frequently in the more severe forms of the disease. Conclusion These data indicate the importance of capillaroscopy in SSc management and that capillaroscopic patterns are directly related to the extent of organ involvement.

Published
2013

28. Assessment of interstitial lung disease in a systemic sclerosis patient cohort using photon-counting detector CT with ultra-high resolution and a 1024-pixel image matrix.

Author

Jungblut L, Sartoretti T, Landsmann A, Nakhostin D, Rabadi T, Mergen V, Jordan S, Mihai CM, Dister O, Frauenfelder T, and Martini K

Subjects
Humans, Female, Retrospective Studies, Male, Middle Aged, Aged, Adult, Radiographic Image Interpretation, Computer-Assisted methods, Photons, Lung diagnostic imaging, Lung Diseases, Interstitial diagnostic imaging, Scleroderma, Systemic diagnostic imaging, Scleroderma, Systemic complications, Tomography, X-Ray Computed methods
Abstract

Objective: This study assessed the potential of ultra-high resolution (UHR) and a 1024-matrix in photon-counting-detector CT (PCD-CT) for evaluating interstitial lung disease (ILD) in systemic sclerosis (SSc) patients., Methods: Sixty-six SSc patients who underwent ILD-CT screening on a first-generation PCD-CT were retrospectively included. Scans were performed in UHR mode at 100 kVp with two different matrix sizes (512×512 and 1024x1024) and reconstructed at slice thicknesses of 1.5 and 0.2 mm. Image noise, subjective image quality, and ILD changes (ground glass opacities and reticulations) were evaluated on a 5-point Likert-scale by two independent readers., Results: Interreader agreement for subjective image quality ranged from fair to almost perfect (Krippendorff-Alpha: 0.258-0.862). Overall image quality was highest for 1.5 mm/1024 matrix images [(reader 1: 4(4.4), reader 2: 5(4.5)]. Image sharpness was rated significantly better in 0.2 mm images (P < .001). Regarding ILD changes, 0.2 mm slice thickness outperformed 1.5 mm slice thickness significantly (P < .001), while there was no significant difference between the two matrix sizes. A 1024-matrix size demonstrated superiority in evaluating coarse reticulations compared to 512-matrix size., Conclusion: UHR mode with a 0.2 mm slice thickness showed enhanced image sharpness and improved visibility of ILD changes compared to standard reconstructions. This has the potential to enable the early detection of subtle disease manifestations., Advances in Knowledge: With the invention of PCD-CT different reconstruction algorithms need to be evaluated for specific pathologies. In our study ILD UHR mode with 0.2 mm slice thickness showed to be beneficial in the detection of parenchymal changes in patients with scleroderma., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Institute of Radiology.)

Published
2024
Full Text
View/download PDF

29. Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients.

Author

Arama SS, Tiliscan C, Negoita C, Croitoru A, Arama V, Mihai CM, Pop F, and Garg A

Abstract

Objective. This study compared the eradication rates of of Helicobacter pylori (HP) infection by a 7-day and 14-day anti-HP regimen. Materials and Methods. An open, randomized, prospective study was performed to evaluate the response to anti-HP treatment in adult HP-positive patients following a 7-day course (Regimen A) of a proton pump inhibitor in association with clarithromycin and amoxicillin compared to a 14-day course (Regimen B). Gastric biopsies were performed at baseline and two months after anti-HP treatment. Results. Seventy-eight patients aged 18-64 years (28 males, 50 females) diagnosed with HP infection were included. Fifty-two (66.7%) patients received Regimen B and 26 (33.3%) Regimen A. The overall eradication rate was 70.5%. Better treatment response (p < 0.01) was seen in Regimen B (44/52, 84.2% versus 11/26, 42.3%). Significant improvement in histological features was seen in regimen B. There has been significant overall reduction in endoscopic aspects of gastric and duodenal lesions in both regimens. Younger patients ≤35 years had a better response to Regimen B. Better treatment response was seen in women, urban residents, and those with tertiary level of education in both groups. Conclusion. 14-day anti-HP regimen offered a significant better overall eradication of HP in study population.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results